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Stress and social isolation are well-known risk factors for psychopathology. However, more
research is needed as to the physiological mechanisms by which social support buffers
the impacts of stress. Research in animal models suggests important roles for proges-
terone (P) and its product, the neuroactive steroid allopregnanolone (ALLO), in stress and
psychopathology. These hormones are produced in brain and periphery during stress in
rodents, and down-regulate anxiety behavior and hypothalamic-pituitary–adrenal axis activ-
ity. Human clinical populations, including depressed patients, have alterations in ALLO
levels, but it is unclear whether these basal hormone level differences have clinical import.
To begin to address this question, this review examines the role of P and ALLO in stress
physiology, and the impact of these hormones on mood, in healthy humans. Evidence
largely supports that P and ALLO increase during stress in humans. However, P/ALLO
administration appears to cause only mild effects on mood and subjective anxiety, while
exerting effects consistent with gamma-aminobutyric acid receptor modulation. Addition-
ally, P is linked to motivation for afﬁliation/social contact; P (and ALLO) release may be
especially responsive to social rejection. These observations lead to the novel hypothesis
that stress-related P/ALLO production functions not only to down-regulate stress and anx-
iety, but also to promote social contact as a long-term coping strategy. Malfunctioning of
the P/ALLO system could therefore underlie depression partly by decreasing propensity
to afﬁliate with others.
Keywords: progesterone, allopregnanolone, 3α-hydroxy-5α-pregnan-20-one, stress, affiliation, social motivation,
psychopathology, depression
INTRODUCTION: THE IMPORTANCE OF
PROGESTERONE-DERIVED HORMONES IN HUMAN EMOTION
AND PSYCHOPATHOLOGY
Stress is a part of life for all vertebrate animals. The physiology of
stress is of utmost importance to study, given decades of research
connecting stress to a host of health issues, ranging from cardio-
vascular health to immune function to psychopathological states
such as depression. While the ﬁelds of behavioral and cognitive
neuroscience tackle the neural pathways of stress and the effects
of stress hormones on the brain, researchers in clinical psychol-
ogy and psychiatry have been exploring the links between stress
physiology and psychopathology; social and personality psychol-
ogists increasingly study human stress hormones in the context of
various social situations. Another growing topic of research con-
cerns the impact of social isolation and social support on health,
including how seeking afﬁliation (positive social contact) and/or
strengthening social bondsmay help protect against adverse effects
of stress.
Two major stress systems have been well-studied: the sym-
pathetic nervous system (SNS) and the hypothalamic-pituitary–
adrenal (HPA) axis, which gives rise to glucocorticoid hormones.
To date,most research on stress physiology in humans has focused
on the HPA axis, particularly the glucocorticoid hormone cor-
tisol, which can be measured non-invasively in saliva. However,
many other stress-related hormones exist. Another steroid hor-
mone, progesterone (P), is best known for its functions in mam-
malian reproduction. However, P and P-derived hormones also
play important roles in stress and in psychological disease states.
P is metabolized to other steroid hormones, including allopreg-
nanolone (ALLO), which have actions on neurons, causing effects
that are relevant for stress, emotion, and behavior. As evidence for
their importance to the brain, P and ALLO are produced not only
by peripheral glands (e.g., ovary; adrenal gland), but also in the
brain itself (Paul and Purdy, 1992).
The role of these hormones in stress, along with their effects
on neuronal transmission, have been studied for decades in ani-
mal models. More recently, evidence has emerged that P and
ALLO are involved in human psychopathology. For reviews of the
growing literature on neurosteroids and psychopathology (see van
Broekhoven and Verkes, 2003; Pisu and Serra, 2004; Dubrovsky,
2006; Eser et al., 2006; N-Wihlback et al., 2006; Girdler and
Klatzkin, 2007; Longone et al., 2008).
P and ALLO have been implicated in mood and anxiety dis-
orders, most notably major depressive disorder (MDD), but also
Premenstrual Dysphoric Disorder (PMDD), Generalized Anxiety
Disorder, Post-Traumatic Stress Disorder (PTSD), and other ill-
nesses (Brambilla et al., 2003; van Broekhoven and Verkes, 2003;
Pisu and Serra,2004;Amin et al., 2006;Dubrovsky,2006; Eser et al.,
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2006; Marx et al., 2006; Rasmusson et al., 2006; Uzunova et al.,
2006; Girdler and Klatzkin, 2007). In laboratory animals, ALLO
and other neurosteroids inﬂuence stress and anxiety, sleep, sexual
behavior, and memory, all of which are involved in the sympto-
matology of depression (Dubrovsky, 2006). Multiple studies have
shown decreased levels of ALLO in the plasma and cerebrospinal
ﬂuid (CSF) of MDD and PTSD patients, as well as in women with
premenstrual syndrome or PMDD (Bicikova et al., 1998; Girdler
et al., 2001; van Broekhoven and Verkes, 2003; Rasmusson et al.,
2006). Interestingly, the decreased ALLO levels seen in depres-
sion normalize with treatment with selective serotonin reuptake
inhibitors (SSRIs) or other antidepressant drugs (Romeo et al.,
1998; Uzunova et al., 1998; Strohle et al., 1999; although not with
non-pharmacological treatments; Schule et al., 2004; Baghai et al.,
2005). ALLO injections exert antidepressant-like effects in rodents
(e.g., in a forced swim test), and SSRIs normalize a decrease in
ALLO seen after prolonged social isolation in rodents, a rodent
model of depression (Guidotti et al., 2001; Rodriguez-Landa et al.,
2007). Thus, there is some evidence that decreased ALLO levels
may be a feature of MDD with clinical signiﬁcance.
Taken together, the evidence strongly points to a connection
between ALLO and depression along with other psychological
disorders. However, it is unclear what causal relationship these
hormones hold with psychopathology. Do low ALLO levels con-
fer risk for developing depression? Or are hormonal changes a
consequence of the disease? Will targeting ALLO help alleviate
depression, or are the lowerALLO levels a“side effect”of the disor-
der with little or no clinical signiﬁcance? Understanding the causal
relationship between ALLO and depression is crucial in order to
develop new treatments and/or identify novel risk factors for this
disease.However, to date there has been very little basic research on
the role of these hormones in the human stress response. In order
to understand the role P and/or ALLO play in psychopathology, it
is necessary to ﬁrst understand the functions of these hormones
in stress, mood, and motivated behavior in healthy humans.
One connection between ALLO and depression may involve
social support and isolation. As social connectedness has well-
documented effects on health and disease, much research has
focused on the physiological mechanisms by which social afﬁli-
ation and bonding help buffer the effects of stress and reduce risk
of psychopathology. Oxytocin, endogenous opioids, and the HPA
axis are among the physiological systems implicated in afﬁliation
and bonding and their stress-protective effects. Recently, evidence
has also emerged linking P and motivation to afﬁliate (Schultheiss
et al., 2004;Wirth and Schultheiss, 2006; Brown et al., 2009;Maner
et al., 2010). One behavioral function that P (by itself, and/or via
conversion to ALLO) may play in stress reduction is to promote
social afﬁliation or bonding with conspeciﬁcs. If so, part of the
import of ALLO levels in depression might be that lower ALLO
levels are connected with depressed individuals’ social isolation,
a feature of depression which puts individuals at greater risk for
worsened mental and physical health.
This review will ﬁrst brieﬂy survey evidence from non-human
animals that P and ALLO are both stress-responsive (i.e., they
increase during stress) and stress-reducing (they down-regulate
stress and anxiety). Next, available literature will be reviewed to
speak towhether/howPandALLOare affectedby stress and in turn
affect subjective stress/anxiety in healthy humans. In addition, this
review will highlight recent ﬁndings from personality and social
psychology linking P with social afﬁliation and rejection. This evi-
dence is crucial to shed light on the role P/ALLO play in mental
health and disease, as social isolation is a key risk factor for psy-
chopathology, and seeking social support may be an important
buffer against the effects of stress. Finally, the current knowledge
from neuroscience, clinical psychology, and social psychology will
be integrated in a broadened theoretical framework for function
of P and ALLO during stress, and a plan for crucial future research
will be described.
NEUROACTIVE STEROIDS AND STRESS: BACKGROUND AND
RESEARCH IN LABORATORY ANIMALS
ALLO belongs to a subset of steroid (cholesterol-derived) hor-
mones called neuroactive steroids, which are produced in the brain
and have “fast” actions on neurons (i.e., changing neuronal excita-
tion) viamembrane-bound receptors. This is in contrast to actions
of steroid hormones on “classical” steroid receptors, which reside
inside the cytoplasm and initiate changes in gene transcription,
leading to slower and more prolonged responses.
In rodents, P and ALLO levels rise in the brain and plasma dur-
ing stress, including swim stress, foot shock, and carbon dioxide
stress (Purdy et al., 1991; Barbaccia et al., 2001). These stress-
related increases are reminiscent of increases in a better-known
class of stress hormones, glucocorticoids, produced by the HPA
axis. Unlike glucocorticoids, however, stress-induced P and ALLO
increases originate not only from the adrenal gland, but from
the brain itself (Purdy et al., 1991; Paul and Purdy, 1992). Brain
levels of these hormones increase during stress even in adrenalec-
tomized, gonadectomized animals (Paul and Purdy, 1992); neu-
rons and glial cells throughout the brain contain the enzymes
necessary for ALLO production (Celotti et al., 1992; Rupprecht,
1997; Magnaghi, 2007). P is an early step in the steroid hormone
synthesis pathway which begins with cholesterol. ALLO, which
is variously known as 3α-hydroxy-5α-pregnan-20-one, 3α,5α-
tetrahydroprogesterone, or 3α,5α-THP, is synthesized from P in
a two-step pathway requiring the enzymes 5α-reductase and 3α-
hydroxysteroid dehydrogenase (Figure 1). These enzymes are
found in the adrenal, gonad, and throughout the brain, including
in the cerebral cortex, hippocampus, and hypothalamus (Com-
pagnone and Mellon, 2000), structures involved in regulating
emotion and memory formation, among other functions.
P or ALLO administration has anxiolytic and sedative effects in
rodents, as well as in humans (Wieland et al., 1991; Paul and Purdy,
1992; Bitran et al., 1995; Soderpalm et al., 2004; Timby et al., 2006).
These effects appear to result from the action of ALLO at recep-
tors for gamma-aminobutyric acid (GABA), the brain’s primary
inhibitory neurotransmitter. As a positive allosteric modulator of
GABA-A receptors,ALLO enhances GABA’s effects on chloride ion
(Cl−) inﬂux, which causes longer-lasting inhibitory post-synaptic
potentials. At high doses, ALLO can also act as a GABA-A agonist
in the absence of GABA (Majewska et al., 1986; Harrison et al.,
1987; Paul and Purdy, 1992; Shu et al., 2004). As a GABA mod-
ulator, ALLO has similar efﬁcacy and potency as benzodiazepines
(Harrison and Simmonds, 1984; Majewska et al., 1986), although
it does not interact with GABA receptors at the benzodiazepine
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FIGURE 1 | Synthesis pathway for progesterone and allopregnanolone. For a complete steroid synthesis pathway including other neurosteroids, see
(Morrow, 2007).
binding site (Brot et al., 1997; Lambert et al., 2003; Akk et al.,
2004a). Thus, P and ALLO are important agents of neuronal inhi-
bition in the mammalian brain, exerting neurochemical effects
similar to classes of drugs used to treat anxiety.
Given ALLO’s effects on GABA activity and anxiety behav-
ior, the stress-induced increases in P and ALLO very likely play
roles in down-regulating or “turning off” the effects of stress. In
support of this idea, ALLO has been shown to affect the HPA
axis: ALLO administration down-regulates gene transcription for
theHPA axis hormones corticotrophin-releasing hormone (CRH)
and arginine vasopressin (AVP) in rodents (Patchev et al., 1994,
1996). These effects suggest that ALLO release during stress is yet
another mechanism (in addition to HPA axis negative feedback,
etc.) to keep this stress hormone system in check.
The anti-stress and anxiolytic effects of P are thought to be
mediated by the conversion of P to ALLO, and ALLO’s actions
at GABA-A receptors, rather than by effects on intracellular P
receptors. For example, blocking P receptors with RU-486 did
not diminish anxiolytic responses to P treatment (Bitran et al.,
1995). Also, mice lacking 5α-reductase (and therefore the abil-
ity to synthesize ALLO from P) lacked some (but not all) of the
anxiolytic and sedative responses to P seen in wild-type controls
(Frye et al., 2004). However, there is some evidence that P may
also exert anti-anxiety effects via mechanisms mediated by classi-
cal intracellular P receptors (Auger and Forbes-Lorman, 2008)1.
Further research must tease apart the behavioral consequences of
actions of P/ALLO on classical steroid receptors vs. membrane-
bound receptors, to better understand the mechanisms by which
these hormones affect stress and anxiety.
Other neurosteroids are also present and active in the brain.
A stereoisomer of ALLO, pregnanolone (3α-hydroxy-5β-pregnan-
20-one,or 3α,5β-THP) is also apositivemodulator atGABArecep-
tors, although some researchers have found that ALLO is more
potent (Norberg et al., 1987; Bitran et al., 1991; Zhu et al., 2001).
The 3α-reduced products of deoxycorticosterone (DOC) also
increase GABA activity. Lack of commercially available antibodies
1ALLO does not bind progesterone receptors (PR). However, the intermediate
steroid step between P andALLO,5α-dihydroprogesterone (5α-DHP),has activity at
PR, and the conversion step from5α-DHP toALLO (mediated by 3α-hydroxysteroid
dehydrogenase) is bi-directional (Compagnone andMellon, 2000;Dong et al., 2001)
Therefore, P may cause activation of PR via P itself or 5α-DHP, as well as changes
to GABA activity via ALLO.
for these other neurosteroids is one reason that few studies have
measured neurosteroids other than ALLO. This review focuses on
ALLO because it appears to be the most potent positive GABA
modulator among the neurosteroids, it is the best-studied neu-
rosteroid to date, and there is evidence that humans have higher
concentrations of ALLO than of other neurosteroids or its isomers
(Parizek et al., 2005; Porcu et al., 2009).
To summarize, cellular and molecular neuroscience work in
laboratory animals has established P andALLOas stress-responsive,
stress-reducing hormones. In rodents, P and ALLO increase in both
blood and brain during stress; in turn, these hormones exert pow-
erful inhibitory effects on neuronal transmission, causing anti-
anxiety and sedative effects; they also down-regulate the HPA axis.
It is logical to suspect that the same would be true in humans, i.e.,
P and ALLO increase during stress and reduce stress and anxiety –
a supposition with far-reaching clinical implications. However,
species differences in stress-related hormonal systems are possi-
ble. This review will synthesize evidence that speaks to whether
P and ALLO are similarly stress-responsive and stress-reducing in
humans.
One important issue to consider when conducting neuroen-
docrinology research in humans is whether peripheral levels of
the hormone reﬂect brain levels; this is particularly an issue with
peptide hormones. Fortunately, P andALLO are steroid hormones
which can cross the blood–brain barrier. Although the blood–
brain barriermay also control entry of steroids via active transport,
studies in rodents report that plasma and brain levels of both P
and ALLO are strongly correlated (Barbaccia et al., 1997, 2001).
Also, in at least one study,ALLO levels were comparable in human
blood andCSF (Kimet al., 2000). Thoughmore studies are needed,
this evidence suggests that measurement of blood levels of ALLO
does give researchers meaningful information about brain levels
of ALLO.
A related issue, however, is determining the source of P and
ALLO increases measured in blood (or in CSF, for that matter),
as these hormones are produced both by the brain and periph-
eral glands. As steroid hormones, presumably they may travel
across the blood–brain barrier in both directions; thus, P/ALLO
produced in the brain could theoretically enter the bloodstream.
However, in rodents a much greater amount of P is produced
in the periphery compared to the brain (Purdy et al., 1991). If
humans are similar, it seems unlikely that a change in brain pro-
duction of P would be detectable in plasma. Hence, increases in
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plasmaPorALLOseen inhumansprobably originate fromperiph-
eral glands (e.g., the adrenal gland.) Nonetheless, these increases
are potentially important for stress and behavior, as steroid hor-
mones of peripheral origin do enter the brain and exert effects
(see, for example, the large literature on effects of glucocorticoids
on memory; Lupien et al., 2007; de Quervain et al., 2009).
It is still possible that neurosteroids are produced selectively
and locally in the brain in amounts too small to detect in the
bloodstream (or CSF), but that have behaviorally relevant effects
by acting at local brain sites. Unfortunately, there are no methods
currently available to measure steroid levels locally in the living
human brain. What can be done with current methods, how-
ever, is to measure levels of P and ALLO that are bathing the
brain (as blood levels seem to reﬂect CSF levels), and likely having
widespread effects.
STRESS-RESPONSIVE? PROGESTERONE AND
ALLOPREGNANOLONE RESPONSES TO STRESS IN HUMANS
Very few studies to date have systematically tested the effects of
stress on P and ALLO levels in humans. As a crucial ﬁrst step,
Genazzani et al. (1998) examined effects on plasma P and ALLO
after a CRH or ACTH challenge in healthy women in the follicular
phase of the menstrual cycle, a time of low levels of circulating P
andALLO.Within 60min after an intravenous bolus of eitherCRH
or ACTH, plasma concentrations of both P and ALLO increased
signiﬁcantly. Thus, the releasing and tropic hormones of the HPA
axis,which are triggeredby stress, cause productionof P andALLO.
The most likely source of this CRH- and ACTH-responsive P and
ALLO is the adrenal gland (see discussion above).
Girdler and colleagues have conducted several studies investi-
gating the roles of P andALLO in premenstrual dysphoric disorder
(PMDD). As part of this work, they have exposed women to lab-
oratory stressors and collected blood for measurement of ALLO.
In one study, luteal-phase women with PMDD and healthy con-
trols underwent a laboratory stressor consisting of making an
audiotaped speech and a completing a challenging arithmetic task
(Girdler et al., 2001). Though overall, healthy women did not
appear to have a signiﬁcant increase in ALLO due to this stressor,
PMDDand control groups differed in their responses to stress: sig-
niﬁcantly more (83%) control subjects had increased ALLO after
stress compared to PMDD subjects (42%; Girdler et al., 2001). In
addition to yielding clues as to the pathophysiology of PMDD,
this study provided further evidence that ALLO increases dur-
ing stress in humans. However, only one post-stress blood sample
was collected (17min after stress onset); it is possible that the
peak ALLO response was not captured. Also, time of day that sub-
jects were tested varied. This could have introduced “noise” in the
P/ALLO stress response data and obscured effects, similarly to how
larger effect sizes are found for HPA/cortisol responses to stress in
the afternoon or evening (when basal cortisol is low and stable)
compared to the morning (Dickerson and Kemeny, 2004).
Interestingly, in the combined (PMDD and control) sam-
ple, Girdler et al. (2001) also documented a negative correlation
between cortisol and ALLO both at baseline/rest and after stress.
This ﬁnding suggests that, as in rats, ALLO down-regulates the
HPA axis in humans.
A later study from this group (Klatzkin et al., 2006b) compared
PMDD-sufferers and controls with and without prior depression
on ALLO responses to a modiﬁed Trier Social Stress Test (TSST;
Kirschbaum et al., 1993), involving a speech delivered to a panel of
judges, followed by amental arithmetic task. In this study, samples
were collected 30 and 60min after stressor onset. Again a group
difference was found in direction of ALLO responses to stress:
women with a prior history of depression were more likely to have
lower ALLO after stress compared to before stress. However, con-
trol subjects did not exhibit a signiﬁcant increase in ALLO due to
stress. As with the 2001 study, it is unclear whether the ﬁndings
indicate that, in general, ALLO does not increase following stress
in humans, or whether the few samples collected failed to pick up
on a short-lived response. Also, although we may assume a rise in
P would drive an increase in ALLO, P was not measured in these
studies.
As these studies were appearing, evidence was emerging that P
does in fact increase in response to stress in humans. The author
and colleagues found positive correlations between P and cortisol
in healthy human subjects across four separate studies, some of
which included arousal of emotional states, but not standard lab-
oratory stressors (e.g., public speaking; Wirth et al., 2007). These
correlations were robust in men and in women taking oral contra-
ceptives (i.e., with suppressed ovarian production of P), but not
in cycling women. This pattern of results is consistent with the
data collected by Genazzani et al. (1998) demonstrating adrenal
production of P during a challenge: in cycling women, ovarian
ﬂuctuations in P appear to “drown out” the relationship otherwise
seen between adrenal cortisol and P,whichmay be released into the
bloodstream simultaneously. In addition to simple correlations,
positive bi-partial correlations (Cohen and Cohen, 1983) were
seen between P and cortisol in all four studies, indicating parallel
changes (whether increases or decreases) in these two hormones
from measurement point to measurement point. Furthermore,
ﬁndings fromone of the studies included in the 2007meta-analysis
suggested that P might especially be responsive to stressors related
to afﬁliation or rejection stress (Wirth and Schultheiss, 2006).
These ﬁndings will be discussed in more depth in “Progesterone
in afﬁliation-seeking,” below.
More recent evidence directly shows that stress can cause
P increases in humans. As part of a larger study investigat-
ing hypotheses related to HPA axis function (at University of
Wisconsin – see Acknowledgments), we collected saliva samples
before and after placement of intravenous catheters, a physical
(pain) as well as social stressor (two experimenters in the room
watching as the nurse placed the lines). Healthy subjects com-
pleted two sessions 48 h apart, both including placement of i.v.
catheters at approximately 16:45–17:00, following a period of rest
and acclimation to the hospital environment. In a subset of sub-
jects for which salivary P and cortisol were analyzed, a P response
to stress was evident that closely paralleled that of cortisol, includ-
ing similar patterns of habituation of the responses from the ﬁrst
to the second session (M.M.Wirth,H. C. Abercrombie, and R. M.
Hoks, unpublished data; Figure 2). Hence, P responds to stress in
humans in a fashion that closely parallels the better-studied stress
hormone cortisol. It may follow that ALLO also responds to stress;
however, ALLO was not measured in these samples.
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FIGURE 2 | Salivary progesterone (top) and cortisol (bottom)
responses to venipuncture stress in humans in two sessions, 48h
apart. Solid line= session 1; dashed line= session 2. Saliva samples were
collected 55 and 25min before and 10, 20, and 30min after venipuncture.
N =11; all women (4) were taking hormonal contraceptives. In session 1,
progesterone was signiﬁcantly higher post-stress (sample #3) compared to
baseline (sample #1), t (11)=2.29, p<0.05.
A short report which appeared in 2004 was the ﬁrst to demon-
strate an ALLO increase during a more naturalistic (“real-world”)
stressor in humans. Students had elevated ALLO during their oral
Ph.D. examination as compared to 4weeks or 45min prior to,
or 4weeks following, the examination. Also elevated were corti-
sol and peripheral benzodiazepine receptors, which play a role in
steroid synthesis (Droogleever Fortuyn et al., 2004).
Recently, the ﬁrst studies systematically examining both P and
ALLO responses to a potent psychosocial stressor (the TSST) were
published (Childs and de Wit, 2009; Childs et al., 2010a). Healthy
men,women in the follicular phase, andwomen in the luteal phase
of the menstrual cycle underwent a TSST and a control task on
separate days while blood samples were collected at multiple time-
points after the stressor/task. Women in the follicular phase and
men had a signiﬁcant increase in P due to stress compared to
control, while luteal-phase women (with roughly 10-fold higher
baseline P levels thanmenor follicular-phasewomen) did not have
a signiﬁcant increase in P due to stress (Childs et al., 2010a). Other
studies by this group also found a signiﬁcant plasma P increase
due to stress in men (Childs and deWit, 2009; Childs et al., 2010b,
placebo group). On the other hand, only luteal-phase women had
a signiﬁcant increase in ALLO in the stress session compared to
the control session (Childs et al., 2010a). Across all three groups,
P and ALLO were not correlated. These data seem to suggest that,
unlike in rodents, P vs. ALLO responses to stress are dissociated
in humans, and ALLO responses to stress only occur in women
in a speciﬁc cycle phase when P and ALLO production is high. It
is also possible (though difﬁcult to test) that in humans, ALLO
concentrations rise in the brain but not in the periphery during
stress.
There are numerous factors that complicate interpretation of
these data. One issue,which the authors acknowledge, is that study
sessions took place in the morning, when steroid hormone levels
tend to be high and variable. The impact of time of day is espe-
cially clear in the cortisol data; the TSST had no signiﬁcant effect
on follicular- or luteal-phase women’s cortisol in this sample, evi-
dently due to a steep decline in cortisol over the course of the
session, which is typical of morning hours. The morning time of
testing could similarly have obscured effects of stress on P and
ALLO, although in the data shown, neither P nor ALLO levels
appear to drop as rapidly as cortisol over the course of the session.
Also of note in these data is that plasma levels of ALLO were
actually found to be three- to four-fold higher than levels of P in
men and in follicular-phase women (luteal-phase women had, on
average, roughly 60% asmuchALLO as P). This could represent an
important difference between human and rat physiology, such that
the bulk of circulating P in humans is quickly converted to ALLO.
However, it is difﬁcult to compare the P and ALLO data since the
two hormones were assayed in two separate laboratories (Childs
et al., 2010a). In earlier reports, plasma P concentrations were
found to be roughly 10-fold higher than ALLO concentrations in
women across the entire menstrual cycle (Genazzani et al., 1998),
and approximately eight-fold higher in men and follicular-phase
women, with a much greater difference in luteal-phase women
(Pearson Murphy and Allison, 2000).
The research described thus far has been essential to further
our understanding of the roles of P and ALLO in stress physiol-
ogy in humans. However, future studies are needed to make ﬁrm
conclusions about the behavior of these hormones during stress.
Laboratory stressors should be administered in the late after-
noon or evening hours for maximal capture of hormonal stress
responses. Care should be taken with selection of analytical meth-
ods; evidence exists that liquid or gas chromatography followed by
mass spectrometry has greater sensitivity and speciﬁcity for ALLO
than radioimmunoassay, as well as being preferable for analysis
of multiple neurosteroids at once (Cheney et al., 1995; Wolthers
and Kraan, 1999; Vallee et al., 2000; Alomary et al., 2001). Another
important factor to consider in investigations of hormonal stress
responses is the presence in the blood of steroid hormone bind-
ing globulins. A proportion of P in the blood is, at any given
time, bound to corticosteroid-binding globulin (CBG) or albu-
min; CBG-bound P is prevented from crossing the blood–brain
barrier (Compagnone and Mellon, 2000), or, presumably, being
converted to ALLO. Differences in plasma concentrations of bind-
ing globulins between men and women in different cycle phases
could affect P/ALLO ratios and ALLO responses to stress. Possible
differences in women taking hormonal contraceptives should also
be addressed.
In summary, evidence thus far largely, but not entirely, sup-
ports P and ALLO increases during stress in humans. Though
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pharmacological stimulation of the HPA axis with CRH or ACTH
caused robust increases in both P and ALLO (Genazzani et al.,
1998), application of laboratory stressors has produced mixed
effects. P increases in response to the TSST were observed in men
and in follicular-phase women, but not in luteal-phase women
(Childs et al., 2010a). The author and colleagues observed close
relationships between P and cortisol in emotion-arousal studies
(Wirth et al., 2007) and in response to venipuncture stress (M. M.
Wirth,H. C. Abercrombie, and R.M.Hoks, unpublished data). An
ALLO increase was evident during Ph.D. examination in one study
(Droogleever Fortuyn et al., 2004). However, in a larger study,
ALLO stress responses were only evident in luteal-phase women
(Childs et al., 2010a), andwere only apparent in a subset of women
in other studies (Girdler et al., 2001; Klatzkin et al., 2006b). Fur-
ther work carefully selecting time of day and method of hormone
analysismay help clarifywhether P andALLOare stress-responsive
hormones in humans, as they are in rats.
STRESS-REDUCING? EFFECTS OF EXOGENOUS
PROGESTERONE AND ALLOPREGNANOLONE IN HUMANS
Do P and ALLO exert similar anxiolytic or stress-reducing effects
in humans as they do in laboratory animals? Evidence suggests
that they do, although the effects may be less dramatic than what
would be expected based on animal research.
When studying effects of exogenous P, it is important to con-
sider the length of time P and ALLO are both elevated in the
blood (and therefore presumably in the CSF). P has a relatively
long half-life, reported at 35–55 h (Wikipedia, 2011). Studies in
humans generally use either oral or intramuscular administration
of P, in doses from 50 to 1000mg. Both administration routes
cause prolonged elevations in plasma levels of both P and ALLO,
with ALLO increasing shortly after the increase in P. For example,
in a study of effects of P on sleep in human males, a single oral
dose of 300mg micronized P at 2130 h (before bed) caused blood
P to be elevated for at least 3 h and ALLO for at least 8 h, with
both peaking around 90min after administration (Friess et al.,
1997). In a study utilizing intramuscular injection, males injected
with 50 or 100mg P still had highly elevated plasma P 4 h follow-
ing the injection (Childs et al., 2010b). Thus, though some P is
rapidly metabolized into ALLO and other products, administra-
tion of P leads to long-lasting elevations of both P and ALLO in
the bloodstream and presumably in the CSF as well.
Administration of P in humans has been associated with mild
increases in fatigue, confusion, and sedation (Freeman et al., 1993;
de Wit et al., 2001; Soderpalm et al., 2004; Klatzkin et al., 2006a).
For example, Klatzkin et al. (2006a) administered 300mg oral
micronized P to healthy women as well as PMDD patient groups
with and without prior depression. This dose raised P to a level
similar as seen in pregnancy, and increased ALLO levels 5- to
20-fold. After controlling for effects of placebo on mood, P treat-
ment was associated with increased confusion and fatigue and
decreased conﬁdence, as rated by study participants on a pre- and
post-treatment Proﬁle of Mood States (POMS) questionnaire, a
commonly used measure of mood in which participants rate how
much they feel a list of feelings right now on a 1–5 scale. Further-
more, women with PMDD reported a decrease in anxiety after P
treatment (Klatzkin et al., 2006a).
de Wit et al. (2001) used intramuscular injections of P, which
cause increases in plasma P and ALLO levels that are less variable
across individuals than oral P. Pre-menopausal, follicular-phase
women receiving 100mg intramuscular P reported decreased
vigor, friendliness, and arousal ratings on the POMS, consistent
with sedative effects of P. Inpost-menopausalwomen, those receiv-
ing 100mg of P reported a delayed (6 h) increase in positive mood
relative to placebo. No effects on subjective state were observed in
post-menopausal women receiving lower doses of P (25 or 50mg).
A later study by this group (Soderpalm et al., 2004) observed sim-
ilarly mild effects on subjective state of 200mg P in men and
women: only an increase in self-reported fatigue was observed,
despite P concentrations in blood around or above those seen
during pregnancy, and highly elevated ALLO.
These subtle effects on mood and anxiety are surprising given
the effects of ALLO at the GABA-A receptor. Several factors could
help explain this discrepancy. Questions may arise as to whether
P/ALLO circulating in the bloodstream reached the brain. How-
ever, as noted previously, steroid hormones are chemically suited
to cross the blood–brain barrier. In rodents, peripherally adminis-
tered P and other steroids enter the brain and exert central effects
(Karavolas et al., 1979; Wang et al., 1997); this is likely also true
in humans (Uzunova et al., 2006). Furthermore, Soderpalm et al.
(2004) do report impaired smooth pursuit (eye movements) in
both men and women given P compared to placebo. Smooth pur-
suit is a measure of motor performance which is highly sensitive
to GABA-active drugs such as benzodiazepines. Thus, these data
indicate that peripheral P administration did exert central effects,
presumably via conversion toALLO either in the periphery and/or
in the brain itself.
As for other factors that could explain the mild and incon-
sistent effects of P/ALLO increases on subjective state, de Wit
and colleagues point out that subjects received acute doses of P;
perhaps subjective effects only emerge after chronic exposure to
high P/ALLO levels. Another possibility is that higher or lower
doses of P/ALLO would exert a greater effect on subjective state.
Many effects of hormones on neurons and on behavior observe an
inverted U-shaped dose-response curve, e.g., the effects of cor-
ticosteroids on memory (de Kloet et al., 1999; Joels, 2006). It
is possible that much smaller doses of P would produce greater
effects on subjective state than the relatively high doses used in
these studies. Circadian factors might also matter; P was admin-
istered in the morning in the studies reported by Klatzkin et al.
(2006b); de Wit et al. (2001) and Soderpalm et al. (2004). Finally,
effects of P/ALLO on subjective states could also depend on stress
or emotional state, a point the authors raised in these reports.
This ﬁnal point was addressed in a recent study by the same
research group (Childs et al., 2010b). Healthy men were injected
with 0, 50, or 100mg P and then exposed to the TSST. In this
study, in the absence of stress, P had no effect on subjective
mood. Interestingly, P treatment reduced some of the responses
to stress, but increased others. 50mg P caused a decrease in the
peak cortisol response to the stressor, and this dose attenuated
the TSST-induced changes in self-reported vigor and drowsiness.
Self-reported anger also returned to baseline faster with 50mg
P compared with placebo. Similarly, 100mg P reduced TSST-
induced changes in vigor and drowsiness, but had no effects on
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anger or cortisol. On the other hand, both doses increased blood
pressure, and 50mg also increased plasma noradrenaline. Thus,
P caused mixed effects on stress-related responses in this study.
The authors help explain these mixed ﬁndings with evidence that
ALLO and other GABA-A modulators exert bimodal/paradoxical
effects, both in humans and laboratory animals: low doses have
been found to increase negative mood and anxiety-like behav-
iors, whereas high doses reduce anxiety. It is also possible that the
brain has various compensatory responses to exogenous neuros-
teroids that would not be evident with endogenous release of these
hormones.
Along these lines, Andreen et al. (2009) point out that anx-
iety, irritability and aggression can result from treatment with
progestins and their associated GABA-active steroids in humans
and other animals. The authors cite evidence that negative mood
symptoms in women with PMDD correspond to levels of P and
ALLO in themenstrual cycle, and that hormone replacement ther-
apy with progestin components can induce negative mood in
post-menopausal women. The authors argue that P and ALLO
have adverse effects on mood (e.g., generating anxiety) at levels
similar to luteal-phase levels in cycling women; at lower or higher
levels these hormonesmay have no effect or have anxiolytic effects.
This approach may help explain why P administration leading to
moderate plasma increases in P and ALLO resulted in an increase
in the response of the amygdala, a key brain structure for negative
affect, to fear and threat stimuli in healthy women (van Wingen
et al., 2008).
Possibly more reliably than effects on subjective mood, neuros-
teroids elicit changes in measures of motor performance sensitive
to sedatives, such as smooth pursuit and saccadic eye velocity. For
example, Soderpalm et al. (2004) found decreased smooth pur-
suit eye movements in both men and women given P. Sundstrom
et al. (1998) demonstrated a reduction in saccadic eye velocity
in healthy women given three 15-mg injections of pregnanolone
(3α,5β-THP;ALLO’s stereoisomer) in both the follicular and luteal
phases of themenstrual cycle. Notably, the effects of pregnanolone
were absent in luteal-phase women with premenstrual syndrome,
suggesting a difference in GABA signaling. More recently, in the
only published report of ALLO itself administered to humans
(Timby et al., 2006), this group showed decreases in saccadic eye
velocity parameters after a total IV dose of 0.9mg/kg ALLO in
follicular-phase women. Women also reported increased sedation
around the time of peak effects on saccadic eye velocity. Moreover,
both subjective sedation ratings and saccadic measures correlated
signiﬁcantly with plasma ALLO levels (Timby et al., 2006). These
ﬁndings strongly suggest that P-related neurosteroids adminis-
tered peripherally do enter the brain and exert central effects
consistent with their known actions at GABA receptors.
Effects of exogenous neurosteroids on cognitive functions have
also been demonstrated, again consistent with GABAergic activ-
ity; other substances which have GABA-facilitatory effects are
well-known to be disruptive to memory formation (e.g., alcohol;
barbiturates; benzodiazepines). P administration was associated
with impaired verbal recall, and greater impairment was associ-
ated with higher plasma ALLO levels (Freeman et al., 1993). In
addition, recent studies report that P or ALLO administration to
humans causedmild impairment of memory for social–emotional
stimuli (emotional faces; van Wingen et al., 2007) or free recall of
words from a list (Kask et al., 2008). These memory effects may
be mediated by the impact of P/ALLO on memory-involved brain
regions such as the amygdala, hippocampus, and fusiform gyrus
(van Wingen et al., 2007). These ﬁndings parallel effects of ALLO
on cognition in rodents: ALLO disrupted memory formation in a
Y-maze task in rats (Ladurelle et al., 2000) and disrupted spatial
learning in a Morris water maze (Johansson et al., 2002; Silvers
et al., 2003).
PROGESTERONE AND AFFILIATION-SEEKING
P andALLO regulatemammalian reproductive behavior; P is well-
known for its facilitative role in both sexual andmaternal behavior
in female rodents. Of note, these hormones also inﬂuence the
expression of other social-afﬁliative behaviors (Frye et al., 2006).
For example, ALLO administration in ovariectomized, estradiol-
treated female rats increased the time they spent in proximity to
male rats; blocking ALLO had the reverse effect (Frye et al., 1998).
Furthermore, at some doses, ALLO reduces aggression toward
another rodent (Miczek et al., 2003; Frye et al., 2006). These obser-
vations point to a possible role for P and ALLO in promoting
afﬁliation, or positive social contact with conspeciﬁcs. There is also
evidence for a role of ALLO in stress related to lack of afﬁliation
or social contact. Social isolation (which is used as a rodent model
of depression or chronic stress) leads to a decrease in brain and
plasma P and ALLO concentrations, as well as changes in GABA
transmission and responses to ethanol that appear to be mediated
by ALLO (Serra et al., 2007). Also, central administration of ALLO
reduces separation distress in rat pups (Zimmerberg et al., 1994).
Schultheiss and colleagues found evidence for a connection
between P and afﬁliation in humans. In one study, implicit afﬁli-
ation motivation – a personality psychology construct measuring
drive for friendly, warm contact with others – was increased in
women taking oral contraceptives containing progestins, as well
as in cycling women in the luteal phase, a time in the cycle of high
P (as well as ALLO) levels (Schultheiss et al., 2003). This corre-
lational ﬁnding prompted experimental studies in which implicit
afﬁliation motivation was manipulated using ﬁlm excerpts, and
effects on P and other hormones were investigated (Schultheiss
et al., 2004; Wirth and Schultheiss, 2006). Among other ﬁndings,
a “rejection”–themed ﬁlm excerpt designed to produce afﬁliation-
related stress caused increases in P as well as cortisol. Further,
among participants exposed to this afﬁliation-related stressor,
baseline (pre-ﬁlm) afﬁliation motivation predicted stress-related
increases in P (but not cortisol; Wirth and Schultheiss, 2006).
This ﬁnding suggests that participants more concerned with
afﬁliation were more impacted by the afﬁliation-related stres-
sor, and hints at a relationship between P and afﬁliation-related
stress.
Given the literature implicating P and ALLO in the down-
regulation of stress, it can be hypothesized that stress-induced P
(and ALLO) increases may partly function to promote afﬁliation
as a stress-coping strategy, similarly to the “tend and befriend”
hypothesis proposed by Shelley Taylor and colleagues regarding
oxytocin (Taylor et al., 2000). Intriguingly, other neuroactive sub-
stances linked to afﬁliation and social bonding, such as opioids and
oxytocin, are also released during stress and exert anxiolytic effects
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(Akil et al., 1984; Kalin et al., 1988; Hashimoto et al., 1989; Uvnas-
Moberg et al., 1994; Uvnas-Moberg, 1998a; da Silva Torres et al.,
2003; Heinrichs et al., 2003; Onaka, 2004; Ribeiro et al., 2005). It
is possible that ALLO release during stress, while down-regulating
stress in the short term by its actions at GABA-A receptors, also
ameliorates stress by promoting afﬁliation and social bonding as
a coping strategy (Wirth and Schultheiss, 2006).
Further work has continued to support a role for P in afﬁlia-
tion and bonding processes in humans. Brown et al. (2009) had
same-sex pairs of participants engage in a task designed to pro-
mote closeness vs. a neutral task. The closeness induction was
associated with an increase in salivary P levels,mirroring effects of
a positive afﬁliation-themed ﬁlm excerpt in the Schultheiss et al.
(2004) study. Furthermore, P increases were associated with each
participant’s stated willingness to sacriﬁce for their partner in the
study (Brown et al., 2009). Recent data collected by Brown and
others supports a connection between P and pro-social (helping)
behavior, including evidence that P is involved in the beneﬁcial
effects of helping behavior on cardiovascular recovery from stress
(Brown and Brown, 2011; Smith, 2011).
Maner et al. (2010) measured salivary P before and after two
different social rejection or exclusion paradigms. They found that
the personality traits determinedhowP responded to thesemanip-
ulations. Those high in social anxiety showed a drop in P in
response to priming exclusion/rejection, which the authors inter-
pret as indicative of the lower motivation to afﬁliate expected in
the socially anxious. In a separate study, those high in rejection
sensitivity showed increased P after a realistic rejection manipula-
tion after which participants were given an opportunity to spend
time with others (Maner et al., 2010). These ﬁndings dovetail with
Wirth and Schultheiss (2006) and add to the evidence of a relation-
ship between P and motivation to afﬁliate, perhaps particularly in
the context of rejection or exclusion.
It is unknown whether this relationship between P and afﬁlia-
tion depends on actions of P at classical intercellular P receptors,
actions of ALLO at GABA-A receptors, or both. Among other con-
straints, ALLO is more difﬁcult to assay and does not seem to be
present at detectable levels in saliva,making it less feasible to mea-
sure ALLO alongside P in psychology research. Future research
must include ALLO manipulation and measurement to hone in
on the neuropharmacological mechanisms by which P/ALLOmay
inﬂuence afﬁliation motivation.
A HYPOTHESIS FOR A BROAD ROLE FOR PROGESTERONE
AND ALLOPREGNANOLONE IN STRESS COPING AND
RECOVERY
The physiological stress response is essential for life, but can be
maladaptive if prolonged (Sapolsky, 2002; Nelson, 2005). There-
fore, there are many physiological “brakes” built into the stress
system. For example, the HPA axis displays negative feedback: glu-
cocorticoids, its output hormones, turn off production of CRH
and ACTH, the hypothalamic and pituitary hormones that lead to
production of glucocorticoids. This way, the necessary rise in glu-
cocorticoids that occurs during stress will be kept short, and levels
will return to baseline. Since the discovery that GABA-active neu-
rosteroids levels increase during stress, it has been hypothesized
that these hormones represent an additional way to down-regulate
the stress response (Purdy et al., 1991; Paul and Purdy, 1992). Pre-
sumably, as levels of neurosteroids such as ALLO rise, they inhibit
neural ﬁring and thereby attenuate anxiety or anxiety-related
behavior. As mentioned previously, ALLO also inhibits CRH and
AVP gene transcription, thereby directly down-regulating theHPA
axis (Patchev et al., 1994, 1996).
Organisms cope with stress behaviorally as well as physio-
logically. For many mammals, but primates in particular, one
important tool for coping with stress is seeking social support.
Research in multiple ﬁelds has documented the positive or pro-
tective health effects of social contact or support in humans, and,
conversely, the detrimental effects of isolation or lack of afﬁliation
on mental and physical health. In humans, lack of social support
is linked to depression, dysfunctional daily cortisol patterns, wors-
ening of disease states, and mortality (House et al., 1988; Prince
et al., 1997; Abercrombie et al., 2004; Boury et al., 2004; Temkin-
Greener et al., 2004). Social support ameliorates stress responses
in laboratory stress paradigms (Heinrichs et al., 2003). Among
couples, marital/relationship quality predicts a number of health
variables (Coyne et al., 2001; Robles and Kiecolt-Glaser, 2003). In
addition, individual differences in implicit afﬁliation motivation
predict long-term health outcomes (McAdams and Vaillant, 1982;
Zeldow et al., 1988; McClelland, 1989).
Thus, afﬁliation and bonding have widespread and powerful
effects on health, but the biological mechanisms behind these
effects are far from clear. Oxytocin, opioids, and the HPA axis
are among the physiological systems implicated in afﬁliation and
bonding and their stress-protective effects (Kalin et al., 1988,
1995; Carter et al., 1992; Fleming et al., 1997; Insel, 1997; Uvnas-
Moberg, 1998b; Depue and Morrone-Strupinsky, 2005). The evi-
dence reviewed above tying P and ALLO to afﬁliation suggests
that these hormones may be another part of the mechanism link-
ing afﬁliation and health. In particular, the rise in P and ALLO
that accompanies stress may function not only to inhibit anxi-
ety on a cellular level (by reducing neuronal activity), but also
to promote behavioral strategies to cope with stress, including
seeking out social contact and social bonds. In this way, these
hormones could underlie both short term (i.e., inhibit the HPA
axis) and longer-term (i.e., form and strengthen social connec-
tions) adaptive responses to stress (Figure 3). If an individual
chooses to seek out others during stress, s/he has the chance to
build long-term resources to help buffer the effects of future chal-
lenges. Of course, behavioral responses to stress are determined by
a host of factors, and hormones generally have modulatory rather
than causal effects on behavior. However, P/ALLO increases dur-
ing stress could be one of many important factors determining the
impact of stress on health.
Importantly, there is evidence that an ALLO increase during
stress is compromised in individuals with a history of depression
(Girdler et al., 2001; Klatzkin et al., 2006b). Decreased or absent
P/ALLO responses to stress could lead to both (1) greater anxi-
ety and/or greater HPA axis responses to stress; and (2) decreased
propensity to seek afﬁliation in the face of stress. A lower P/ALLO
response to stress could represent both a risk factor for depression,
and/or could help explain some of the features of depression, such
as worsening of symptoms during stress and decreased social con-
tact. Given growing evidence for the importance of P/ALLO in
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FIGURE 3 | Neural, genetic, and behavioral effects of progesterone (P)
and allopregnanolone (ALLO). Black border indicates functions that may be
compromised with a decreased ALLO response to stress in depression.
Dotted lines indicate relationships that need further study.
stress, afﬁliation and affective disorders, it is crucial to elucidate the
role these hormones play in emotional processes in both healthy
and depressed individuals.
FUTURE DIRECTIONS: UNDERSTANDING P AND ALLO
FUNCTION IN STRESS AND PSYCHOPATHOLOGY
P and ALLO appear to be stress-responsive, stress-reducing hor-
mones in rodents. In addition, multiple studies have found
decreased ALLO in depressed patients compared with healthy
controls. To understand the import of these clinical ﬁndings, it
is necessary to extend our knowledge from laboratory animal
research into humans. The evidence reviewed above is largely in
support of P and ALLO increases during stress in humans; there is
mixed evidence for effects of these hormones on subjective mood
and anxiety.
In addition, evidence is accumulating for a link between P
and motivation to afﬁliate. These ﬁndings suggest the hypotheses
that: (1) P/ALLO increases during stress function in part to pro-
mote afﬁliation and bonding as a long-term coping strategy; and
(2) diminished P/ALLO responses to stress could be a risk factor
for depression, and/or could underlie certain features of depres-
sive disorders, such as less propensity to seek out social contact
(Figure 3).
In order to better understand the functions of P and ALLO
in stress, and what relevance they may have for psychopathol-
ogy, further basic research in human subjects is needed in
order to (1) establish more ﬁrmly whether these hormones are
stress-responsive and stress-reducing in humans; (2) uncover clues
about cause and effect with regards to ALLO and depression; (3)
explore the relevance of P andALLO for (stress-related) afﬁliation-
seeking; and (4) studyhow these hormones affect the humanbrain.
This research will by necessity be interdisciplinary, including per-
spectives from physiological psychology; cognitive neuroscience;
clinical psychology; and social/personality psychology. Such basic
research will form the groundwork for potential future clinical
applications: P and ALLO may emerge as important biological
markers of disease states (e.g., risk of developing depression),
and drugs designed to impact the synthesis or actions of these
neuroactive steroids may have treatment potential.
P AND ALLO: STRESS-RESPONSIVE AND STRESS-REDUCING IN
HUMANS?
The function of P andALLO in stress needs to be explored further.
Evidence thus far shows that P and ALLO both may be stress-
responsive in humans, but conﬂicting results have been obtained
as towhether eachhormone increases during stress inmen,women
(in particular cycle phases), or both (Droogleever Fortuyn et al.,
2004; Wirth and Schultheiss, 2006; Childs et al., 2010a; Maner
et al., 2010). Future research should explore the effects of vari-
ous stressors on these hormones, alongside HPA axis hormones,
carefully controlling for circadian and other factors and utilizing
the best available methods for P and ALLO measurement, ideally
quantifying both simultaneously using mass spectrometry. It may
be the case such that P/ALLO stress responses are not universal in
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humans, but depend on state factors (e.g., construal of the stressor;
menstrual phase) or individual differences (e.g., sex; personality
traits). These differences, if they exist, should be further elucidated.
If P and ALLO are impacted by stress in a healthy popula-
tion, they then need to be compared in patient groups such as
those suffering from Major Depressive Disorder. Although evi-
dence exists that those with a history of depression exhibit lower
or absent ALLO responses to stress (Girdler et al., 2001), studies
using standardized stress protocols (e.g., the TSST) and with ade-
quate sampling to capture a stress response will help ﬂesh out this
evidence. In addition, asMDDhas considerable co-morbiditywith
anxiety disorders and substance abuse, and as these have also been
associated with alterations in neurosteroids, P/ALLO responses to
stress should be examined in co-morbid groups as well as inMDD
patients without other diagnoses.
Finally, more work is needed to elucidate under what circum-
stances and what doses of P or ALLO impact mood and emotional
processing in humans. If these steroids exert paradoxical effects
on mood (Andreen et al., 2009), it is important to delineate the
doses and conditions under which beneﬁcial mood effects might
be obtained by manipulating P or ALLO levels. Use of drugs that
block conversion of P to ALLO, such as ﬁnasteride or dutasteride,
may help uncover whether mood effects of these hormones are
mediated by ALLO’s effects on GABA-A receptors; P or 5α-DHP’s
actions at P receptors (see text footnote 1); or both.
ALLO AND DEPRESSION: CAUSE AND EFFECT
If the evidence continues to support a difference in P/ALLO
functioning between healthy individuals and patients, the next
question that must be addressed is whether there is a causal
relationship between P/ALLO responses and psychopathology.
For example, lower P/ALLO responses to stress could be deter-
mined by genetic factors and/or early life experiences and could
pose a risk factor for development of psychopathology. Alterna-
tively, depression itself could be the cause of diminished P/ALLO
responses to stress; the hormonal changes could then lead to
exacerbation of the disorder by predisposing the individual to
greater anxiety and HPA axis activity during stress, and decreased
propensity to seek social support. These two possible cause-effect
relationships are not mutually exclusive; each must be tested sep-
arately. To test whether reduced P/ALLO contributes to a risk for
depression, for example, longitudinal studies in currently healthy,
at-risk populations could be employed. This approach could
yield important information about new biological risk factors for
depression.
It is also unclear whether the reducedALLO levels seen inMDD
are tied to the symptomatology of MDD; that is, whether increas-
ing ALLO levels would alleviate symptoms. In rodent models of
depression, ALLO does reduce depression-like behavior (Khisti
et al., 2000; Guidotti et al., 2001; Rodriguez-Landa et al., 2007).
However, human depression can be successfully treated (with non-
pharmacological means) without increased ALLO accompanying
the improvement (Schule et al., 2004; Baghai et al., 2005). Longi-
tudinal studies examining basal and stress-responsive P andALLO
levels before depression onset and after recovery can help inform
whether pharmacological treatments aimed at increasing ALLO
production or activity should be pursued.
P AND ALLO IN AFFILIATION-SEEKING
The evidence for a relationship between P and afﬁliation moti-
vation is still sparse. Future research both in animal models and
in humans is needed to delineate this relationship. In particular,
in order to establish a causal relationship, hormone manipula-
tion studies are necessary. Elucidation is needed as to whether
the proposed P-afﬁliation relationship is mediated by P itself, act-
ing at intercellular P receptors, or mediated by the conversion
of P to ALLO and actions at GABA-A receptors. Further, it is of
interest whether this purported P/ALLO-afﬁliation relationship is
disrupted in depression or other disorders. A better understand-
ing of the relationships between stress, afﬁliation, and hormones
could lead to behavioral interventions, e.g., to increase afﬁliation
and social support-seeking, as preventative and adjunct treatment
options.
HOW P AND ALLO AFFECT THE HUMAN BRAIN
There are obvious limitations towhat can be understood about the
function of hormones in stress,mood, and afﬁliation only bymea-
suring or manipulating peripheral levels of hormones. In order to
uncover the neural mechanisms of the effects of P and ALLO on
mood and behavior, brain imaging methods must be employed,
along with pharmacological manipulations. One important ques-
tion is whetherGABA activity in the human brain parallels periph-
eral release of P during stress. This question might be addressed
using positron emission tomography (PET) imagingwith radioac-
tive ligands for the GABA-A receptor. Unfortunately, currently
only radioligands for the benzodiazepine binding site are available.
ALLO appears to bind to a different site, as yet uncharacterized
(Brot et al., 1997; Lambert et al., 2003; Akk et al., 2004b). Another
approachmight be to use protonmagnetic resonance spectroscopy
(H1-MRS) to gain information regardingGABA concentrations in
different brain regions (Epperson et al., 2002, 2006). GABA con-
centrations may ﬂuctuate in emotion-related brain areas during
stress or pharmacological manipulation of P/ALLO.
CONCLUSION
Neuroscience research in rodents has established a crucial role
for P and ALLO in stress, while clinical research comparing
patient groups to healthy controls strongly suggests dysregula-
tion in neurosteroids in affective and other disorders. In order
to understand the signiﬁcance of P/ALLO differences between
patients and controls, it is necessary to know more about the
basic physiology and psychology of these hormones in humans.
The available evidence suggests that, like in rodents, both P
and ALLO increase during stress in humans, but more sys-
tematic studies are needed. Although neurosteroids are indirect
GABA agonists and appear to cause anxiolysis in rodents, the
evidence thus far suggests that P/ALLO administration causes
mild (if any) effects on mood and subjective anxiety in humans.
In fact, some individuals may respond to P/ALLO with adverse
mood effects (Andreen et al., 2009). In contrast, administration
of these hormones do exert effects in humans consistent with
GABA agonists, such as effects on saccadic eye velocity (Sund-
strom et al., 1998; Timby et al., 2006) and on memory (Freeman
et al., 1993; van Wingen et al., 2007; Kask et al., 2008). Mean-
while, a growing social psychology literature suggests a connection
between P and motivation for afﬁliation/social contact (Wirth
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and Schultheiss, 2006; Brown et al., 2009; Maner et al., 2010).
P may be especially responsive to social rejection (Wirth and
Schultheiss, 2006; Maner et al., 2010). This connection suggests
another possible role for P/ALLO rises in response to stress,
namely, to promote social contact as a long-term coping strategy.
If so, P/ALLO could be a risk factor for depression in part by way
of a decreased propensity to afﬁliate. Further work is needed to
answer these questions, which will require collaboration between
researchers in neuroendocrinology, social psychology, and clinical
psychology/psychiatry.
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